Welcome to Mesothelioma.net - Turning Hope and Faith into Action.

Research Reveals Platinum Drug Provides Superior Result in HIPEC Treatment

The most recent edition of the journal The American Surgeon contains the result of a study recently conducted by surgeons at Creighton University Medical Center in Omaha, Nebraska.  The surgeons were investigating whether there was a difference in the outcomes between mesothelioma patients who had received two different types of chemotherapy following an innovative surgery known as CRS/HIPEC. The procedure involves cytoreductive surgery aimed at surgically removing as much cancerous tissue as possible, and then following the debulking with a wash of heated chemotherapeutic agents. Though chemotherapy alone has produced some success, the procedure that combines the two therapies has generally shown great promise in patients, and a significant increase in survival in those who have had it performed.

In the study, the researchers reviewed retrospective data on the outcomes of 44 patients who had undergone the CRS/HIPEC procedure over a seven year time span. In some of the surgeries the wash that was used was made of carboplatin, while other patients’ wash was made of an antibiotic cancer drug called mitomycin.  The study revealed that those who had been treated with carboplatin, a platinum-based drug, had better survival rates.

According to lead author Shreya Shetty, “HIPEC with carboplatin in diffuse malignant peritoneal mesothelioma is associated with improved overall survival and shorter hospital stay compared with HIPEC with mitomycin.” The study showed that the patients who had the carboplatin wash required six less days of hospitalization following surgery than did those treated with mitomycin, and of that time they spent a quarter of the time recovering in intensive care. It is also notable that the group treated with mitomycin required four times as many blood transfusions. The overall result of the procedure was that ninety percent of the carboplatin patients lived for a full year following the surgery while in the group that had received the mitomycin wash only 72 percent were alive. Similarly and most significantly, the group that received the cisplatin wash saw 62.5 percent of patients still alive five years after the surgery, representing a tremendous success rate. In the group that had the mitomycin wash only 27 percent were still alive five years later.

Terri Oppenheimer

Terri Oppenheimer is an experienced blog writer, editor, and proofreader. She graduated from the College of William and Mary with a degree in English. She specializes in providing content for websites and finds tremendous enjoyment in the things she learns while doing her research. Her specific areas of expertise include health, medical research, and law.

Get Your FREE Resources Sent Overnight

  • New treatment options
  • Veterans benefits & claims
  • $30 Billion asbestos trust fund information

– Or Call –

Site Navigation

Where can I

Get Additional Help?

For over 15 years, we’ve provided the best FREE resources to mesothelioma patients and loved ones. Our resources include information on the leading treatment options and best doctors in your area; lessons learned from survivors; claims and benefits specifically for Veterans; and how to access your share of billions of dollars in trust fund money.

Get Your FREE Resources Sent Overnight

  • New Treatment Options
  • Veteran's Benefits & Claims
  • $30 Billion Asbestos Trust Fund Information

– Or Call –

We are here to help you


If you've been diagnosed with asbestos-related cancer, contact us at 1-800-692-8608 to find out if you are eligible to receive compensation. You can also fill out the form above to receive FREE information.

Quick Compensation - $30 Billion Trusts
$30 Billion Asbestos Trusts
Get Started